2025
Co-expression network-based analysis of gene programs contributing to immune checkpoint inhibitor (ICI) resistance in renal cell carcinoma (RCC).
Malik R, Rout R, Kashima S, Saad E, Kane H, Shah V, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Signoretti S, McGregor B, McKay R, Atkins M, Van Allen E, Choueiri T, Braun D. Co-expression network-based analysis of gene programs contributing to immune checkpoint inhibitor (ICI) resistance in renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: 4530-4530. DOI: 10.1200/jco.2025.43.16_suppl.4530.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaImmune cellsImmune infiltrationSignature scoreRCC tumor microenvironmentResistance to immune checkpoint inhibitorsAssociated with worse PFSICI-based therapyScRNA-seq dataGene programCD8+ TPhase II trialICI resistanceImmune-lowCheckpoint inhibitorsRibosomal proteinsCD4+II trialPrognostic roleRenal cell carcinoma tumor sampleRNA-seqCell carcinomaTumor microenvironmentScRNA-seq
2024
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer
Feng B, Bai Z, Zhou X, Zhao Y, Xie Y, Huang X, Liu Y, Enbar T, Li R, Wang Y, Gao M, Bonati L, Peng M, Li W, Tao B, Charmoy M, Held W, Melenhorst J, Fan R, Guo Y, Tang L. The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature 2024, 634: 712-720. PMID: 39322665, PMCID: PMC11485240, DOI: 10.1038/s41586-024-07962-4.Peer-Reviewed Original ResearchCD8+ T cellsMammalian target of rapamycinCancer immunotherapyT cellsNext-generation cancer immunotherapyAdoptive T-cell transferImmune checkpoint blockade therapyLong-term complete remissionCurrent cancer immunotherapiesCheckpoint blockade therapyInduce durable remissionsT-cell transferCD8+ TCytokine-based immunotherapyType 2 cytokinesXenograft tumor modelBlockade therapyDurable remissionsComplete remissionAntitumour efficacyTumor modelTarget of rapamycinInterleukin-4Immune responseCD8NCF4 attenuates colorectal cancer progression by modulating inflammasome activation and immune surveillance
Li L, Mao R, Yuan S, Xie Q, Meng J, Gu Y, Tan S, Xu X, Gao C, Liu H, Ma C, Man S, Meng X, Xu T, Qi X. NCF4 attenuates colorectal cancer progression by modulating inflammasome activation and immune surveillance. Nature Communications 2024, 15: 5170. PMID: 38886341, PMCID: PMC11183137, DOI: 10.1038/s41467-024-49549-7.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCARD Signaling Adaptor ProteinsCD8-Positive T-LymphocytesCell Line, TumorColorectal NeoplasmsDisease ProgressionFemaleHumansImmunologic SurveillanceInflammasomesInterleukin-18Killer Cells, NaturalMaleMiceMice, Inbred C57BLMice, KnockoutNADPH OxidasesNLR Family, Pyrin Domain-Containing 3 ProteinPhosphorylationReactive Oxygen SpeciesConceptsInflammasome activationColorectal cancerFive-year survival rateAssociated with colorectal cancer developmentAnti-tumor responsesCD8+ TColorectal cancer developmentColorectal cancer progressionApoptosis-associated speck-like proteinNK cellsImmune surveillanceRegulation of inflammasome activationSpeck-like proteinCancer developmentSurvival rateCancer progressionColorectal tumorigenesisPrecancerous cellsTransit amplifyingAIM2 inflammasome activationImmunoprecipitation-mass spectrometry analysisInflammasome responsesNCF4Modulating inflammasome activationROS levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply